- Conditions
- Venous Stenosis, Venous Occlusion
- Interventions
- Merit WRAPSODY Endovascular Stent Graft, PTA
- Device
- Lead sponsor
- Merit Medical Systems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 33
- States / cities
- Tempe, Arizona • Tucson, Arizona • Orange, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 22,488
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
- Interventions
- Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2035
- U.S. locations
- 1160
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
- Conditions
- Ulcerative Colitis
- Interventions
- Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
- Interventions
- JDQ443, TNO155, tislelizumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Kidney Disease
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 37 more
- Conditions
- Heart Failure, Cardiomyopathies
- Interventions
- EXCOR Pediatric
- Device
- Lead sponsor
- Berlin Heart, Inc
- Industry
- Eligibility
- 1 Day to 16 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more
- Conditions
- Kidney Failure, Chronic
- Interventions
- Placebo, Genz-644470, Sevelamer carbonate
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 52
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more
- Conditions
- Pregnancy, Smoking
- Interventions
- Health & Wellness Intervention, Questionnaire, Mood Management Intervention
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- YTB323
- Genetic
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Scleroderma
- Interventions
- MEDI-546
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 7 more
- Conditions
- Open Angle Glaucoma
- Interventions
- Streamline Surgical System, iStent Inject W
- Device
- Lead sponsor
- New World Medical, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 18
- States / cities
- Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more
- Conditions
- End-stage Renal Disease, Kidney Failure, Chronic
- Interventions
- HAVG
- Biological
- Lead sponsor
- Humacyte, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Houston, Texas • Norfolk, Virginia
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Interventions
- Azacitidine, Durvalumab
- Drug · Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
- Conditions
- Education, Cervical Dysplasia
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
- Interventions
- PRT3789, Docetaxel
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more
- Conditions
- Postoperative Pain
- Interventions
- Dexamethasone, Clonidine, Normal Saline
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 6 Months to 6 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms, NUT Carcinoma
- Interventions
- BI 894999
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- HspE7 and Poly-ICLC
- Biological
- Lead sponsor
- Nventa Biopharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Augusta, Georgia + 5 more
- Conditions
- COVID-19, SARS-COV-2 Infection
- Interventions
- BNT162b2 Vaccine, Placebo
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 5,240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 196
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- CG-806
- Drug
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
- Interventions
- XmAb20717
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR b.i.d. (Twice Daily)
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more